TIDMREDX
RNS Number : 6245S
Redx Pharma plc
07 November 2023
THIS ANNOUNCEMENT, AND THE INFORMATION CONTAINED HEREIN, IS
RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN
WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE
UNITED STATES, CANADA, AUSTRALIA, JAPAN, THE REPUBLIC OF SOUTH
AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION
OR DISTRIBUTION WOULD BE UNLAWFUL.
FURTHER, THIS ANNOUNCEMENT IS MADE FOR INFORMATION PURPOSES ONLY
AND DOES NOT CONSTITUTE AN OFFER TO SELL OR ISSUE OR SOLICITATION
TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE SHARES IN REDX PHARMA
PLC IN ANY JURISDICTION.
THE SECURITIES DISCUSSED HEREIN MAY NOT BE OFFERED OR SOLD IN
THE UNITED STATES, UNLESS REGISTERED UNDER THE U.S. SECURITIES ACT
OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR PURSUANT TO AN
EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, REGISTRATION
UNDER THE SECURITIES ACT. NO PUBLIC OFFERING OF THE SECURITIES
DISCUSSED HEREIN IS BEING MADE IN THE UNITED STATES AND THE
INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE AN OFFERING OF
SECURITIES FOR SALE IN THE UNITED STATES AND THE COMPANY DOES NOT
CURRENTLY INTEND TO REGISTER ANY SECURITIES UNDER THE SECURITIES
ACT. ADDITIONALLY, THE SECURITIES HAVE NOT BEEN APPROVED OR
DISAPPROVED BY THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION
OR ANY OTHER SECURITIES COMMISSION OR REGULATORY AUTHORITY IN THE
UNITED STATES, NOR HAVE ANY OF THE FOREGOING AUTHORITIES PASSED
UPON OR ENDORSED THE MERITS OF THE SUBSCRIPTION. ANY REPRESENTATION
TO THE CONTRARY IS A CRIMINAL OFFENCE IN THE UNITED STATES.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES
OF ARTICLE 7 OF EU REGULATION 596/2014 AS IT FORMS PART OF DOMESTIC
LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION
(WITHDRAWAL) ACT 2018.
REDX PHARMA PLC
("Redx" or "the Company")
Admission of Subscription Shares and Total Voting Rights
Alderley Park, 7 November 2023, Redx (AIM: REDX), the
clinical-stage biotechnology company focused on discovering and
developing novel, small molecule, targeted therapeutics for the
treatment of fibrotic disease and cancer, announces that the
admission to trading on AIM of the 54,074,458 Subscription Shares
referred to in the announcement of the Results of General Meeting
on 6 November 2023 became effective at 8:00 a.m. this morning.
Key highlights
-- Subscription for 54,074,458 Subscription Shares at the Issue
Price of 26 pence per Subscription Share to raise GBP14,059,359
(before expenses) by existing shareholders.
-- One of the Redmile Funds, which taken together are the
Company's largest shareholder, has participated in the Subscription
and has subscribed for 31,548,692 Subscription Shares at the Issue
Price. Sofinnova Partners, an existing Shareholder, has also
participated in the Subscription and has subscribed for 7,887,173
Subscription Shares at the Issue Price. In addition, Polar Capital
and Invus, both existing shareholders of the Company, have also
participated in the Subscription, either directly or through
entities in their respective groups.
Following Admission, the number of Ordinary Shares in issue and
the number of total voting rights will be 388,985,916. The figure
of 388,985,916 Ordinary Shares may be used by Shareholders as the
denominator for the calculations by which they will determine
whether they are required to notify their interest in, or a change
to their interest in, the Company under the Financial Conduct
Authority's Disclosure Guidance and Transparency Rules.
Capitalised terms used but not defined herein shall have the
same meanings given to them in the announcement of the Subscription
by the Company on 18 October 2023.
The person responsible for the release of this announcement on
behalf of the Company is Nischal Hindia, Interim General Counsel
& Company Secretary.
For further information, please contact:
Redx Pharma plc T: +44 (0)1625 469
Caitlin Pearson, Head of Communications ir@redxpharma.com 918
UK Headquarters
Lisa Anson, Chief Executive Officer
US Office
Peter Collum, Chief Financial Officer
SPARK Advisory Partners (Nominated Adviser) T: +44 (0)203 368
3550
Matt Davis/ Adam Dawes
MTS Securities, LLC (Exclusive Placement T: +1 212 887 2100
Agent)
Mark Epstein
WG Partners LLP (Joint Broker) T: +44 (0)203 705
9330
Claes Spång/ Satheesh Nadarajah/ David
Wilson
Panmure Gordon (UK) Limited (Joint Broker) T: +44 (0)207 886
2500
Rupert Dearden/ Freddy Crossley/ Emma Earl
FTI Consulting T: +44 (0)203 727
1000
Simon Conway/ Ciara Martin
About Redx Pharma Plc
Redx Pharma (AIM: REDX) is a clinical-stage biotechnology
company focused on the discovery and development of novel, small
molecule, targeted therapeutics for the treatment of fibrotic
disease, cancer and the emerging area of cancer-associated
fibrosis, aiming initially to progress them to clinical proof of
concept before evaluating options for further development and
potential value creation. The Company's lead fibrosis product
candidate, the selective ROCK2 inhibitor, zelasudil (RXC007), is in
development for interstitial lung disease and is undergoing a Phase
2a trial for idiopathic pulmonary fibrosis (IPF) with topline data
expected in H1 2024. The Company's second fibrosis candidate,
RXC008, a GI-targeted ROCK inhibitor for the treatment of
fibrostenotic Crohn's disease, is progressing towards a CTA
application during the fourth quarter of 2023. Redx's lead oncology
product candidate, the Porcupine inhibitor RXC004, being developed
as a targeted treatment for Wnt-ligand dependent cancers, is
expected to report anti-PD-1 combination Phase 2 data during the
first half of 2024, following which Redx will seek a partner for
ongoing development. In October 2023, Redx nominated its next
development candidate, RXC009 a highly potent and selective DDR1
inhibitor for the treatment of chronic kidney disease and
associated fibrosis.
The Company has a strong track record of discovering new drug
candidates through its core strengths in medicinal chemistry and
translational science, enabling the Company to discover and develop
differentiated therapeutics against biologically or clinically
validated targets. The Company's accomplishments are evidenced not
only by its wholly-owned clinical-stage product candidates and
discovery pipeline, but also by its strategic transactions,
including the sale of pirtobrutinib (RXC005, LOXO-305), a
non-covalent (reversible) BTK inhibitor now approved by the US FDA
for adult patients with mantle cell lymphoma previously treated
with a covalent BTK inhibitor, and AZD5055/RXC006, a Porcupine
inhibitor targeting fibrotic diseases including IPF, which
AstraZeneca is progressing in a Phase 1 clinical study. In
addition, Redx has forged collaborations with Jazz Pharmaceuticals,
which includes JZP815, a pan-RAF inhibitor developed by Redx which
Jazz is now progressing through Phase 1 clinical studies, and an
early stage oncology research collaboration.
To subscribe to Email Alerts from Redx, please visit:
www.redxpharma.com/investor-centre/email-alerts/ .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCGIBDBLGGDGXR
(END) Dow Jones Newswires
November 07, 2023 03:10 ET (08:10 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Nov 2024 to Dec 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Dec 2023 to Dec 2024
